Table 1 Substance treatment details.
Compound | Rasagiline | Safinamide | Flecainide | Phenytoin |
|---|---|---|---|---|
Administration form | Oral administration | Oral administration | Subcutaneous injection | Subcutaneous injection |
Concentration | 5 mg/kg/bw | 8 mg/kg/bw | 30 mg/kg bw | 50 mg/kg bw |
Mode of action | Selective MAO-B inhibition | Reversible MAO-B inhibition Sodium and calcium channel blocking Glutamate release inhibition Dopamine and serotonin reuptake inhibition | Selective NaV1.5 sodium channel blocker | Unselective NaV1.1, NaV1.2, NaV1.3, NaV1.5 and NaV1.6 sodium channel blocker |
Treatment interval | Daily | Daily | Daily | 3 times/week |
Treatment start | Directly p.i | Directly p.i | Directly p.i | Directly p.i |
CAS Corresponding treatment reference | 161735-79-1 (Sigma Aldrich) | 202825-46-5 (Sigma Aldrich) | 54143-56-5 (Sigma Aldrich) | 630-93-3 (Sigma Aldrich) |
